About: Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID‐19
Creator	Nakagawa, Atsushi Eto, Masaaki Fujita, Hirotoshi Hashida, Tohru Ikesue, Hiroaki Irie, Kei Muroi, Nobuyuki Tamura, Ryo Tomii, Keisuke
Source	Medline; PMC
abstract	Since December 2019, a novel coronavirus (SARS‐CoV‐2) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID‐19). The anti‐retroviral drug favipiravir (FPV) has been experimentally used for COVID‐19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high‐performance liquid chromatography in patients with severe COVID‐19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1600 mg of FPV twice daily on Day 1, followed by 600 mg twice daily from Day 2 to Day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty‐nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8–12 h) concentrations of most samples were lower than the lower limit of quantification (1 µg/mL) and EC(50) (9.7 µg/mL) against SARS‐CoV‐2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID‐19.
has issue date	2020-05-31(xsd:dateTime)
bibo:doi	10.1111/cts.12827
bibo:pmid	32475019
has license	cc-by-nd
sha1sum (hex)	45d1a31891f920b9dce589e87f7065a1707feed0
schema:url	https://doi.org/10.1111/cts.12827
resource representing a document's title	Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID‐19
has PubMed Central identifier	PMC7300626
has PubMed identifier	32475019
schema:publication	Clin Transl Sci
resource representing a document's body	covid:45d1a31891f920b9dce589e87f7065a1707feed0#body_text
is schema:about of	named entity '2019' named entity 'infection' named entity 'causing' named entity 'coronavirus disease 2019' named entity 'coronavirus' named entity 'mechanical ventilation' named entity 'mechanical ventilation' named entity 'COVID-19' named entity 'Waldbronn' named entity 'Declaration of Helsinki' named entity 'Serum concentrations' named entity 'mechanical ventilation' named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'substrates' named entity 'serum' named entity 'Houston' named entity 'acute respiratory distress syndrome' named entity 'tocilizumab' named entity 'COVID' named entity 'COVID' named entity 'COVID-19' named entity 'ICU' named entity 'serum samples' named entity 'Agilent' named entity 'radiography' named entity 'clinical trial' named entity 'JIKI' named entity 'mechanical ventilation' named entity 'COVID' named entity 'partial pressure of arterial oxygen' named entity 'influenza virus' named entity 'distribution volume' named entity 'compassionate-use' named entity 'critically ill patients' named entity 'personal protective equipment' named entity 'critically ill patients' named entity 'critically ill patients' named entity 'COVID' named entity 'mechanical ventilation' named entity 'Toyama Chemical' named entity 'ICU' named entity 'AVIGAN' named entity 'critically ill patients' named entity 'lung' named entity 'observational study' named entity 'Lancet' named entity 'COVID' named entity 'pathology' named entity 'metabolized' named entity 'COVID' named entity 'mechanical ventilation' named entity 'positive-sense single-stranded RNA virus' named entity 'influenza' named entity 'serum' named entity 'ICU' named entity 'critically ill patients' named entity 'mechanical ventilation' named entity 'bioavailability' named entity 'influenza virus' named entity 'intubation' named entity 'hepatic' named entity 'drug development' named entity 'septic shock' named entity 'nasogastric tube' named entity 'COVID' named entity 'critically ill patients' named entity 'blood sampling' named entity 'pandemics' named entity 'extracorporeal membrane oxygenation' named entity 'AVIGAN' named entity 'clinical trial' named entity 'package insert' named entity 'intubated'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software